港股异动丨药明生物高开3.55%，料去年多赚46%

Core Viewpoint - WuXi Biologics (2269.HK) has announced a positive earnings forecast, expecting a significant increase in shareholder profit and revenue by the end of 2025, driven by successful strategic execution and advanced technology platforms [1] Financial Performance - The company anticipates a 46.3% increase in shareholder profit to 4.908 billion HKD by the end of 2025 [1] - Adjusted net profit is expected to rise by 22% to 6.586 billion HKD [1] - Revenue is projected to grow approximately 16.7% to 21.79 billion HKD [1] Growth Drivers - The growth is attributed to the successful execution of the "Follow and Win Molecule" strategy and the utilization of leading technology platforms [1] - The company has expanded its service offerings in the biopharmaceutical industry, including research and discovery services, pre-IND development services, and clinical and commercial production services [1] - Revenue growth from advanced technology research services and increased utilization of existing and new production capacities, including ramp-up at European production facilities [1] Operational Efficiency - Cost savings and efficiency improvements have been achieved through the WuXi Biologics Lean Operations Management System (WBS) and digital solutions [1] - Investment returns from the company's investment portfolio have also contributed to overall growth [1]